Charles (Chas) McKhann has been the Chief Executive Officer of Silk Road Medical, Inc. since November 2, 2023. He holds a B.A. in Political Science and Economics as well as an M.B.A. from Stanford University, which gives him a strong...

Charles (Chas) McKhann has been the Chief Executive Officer of Silk Road Medical, Inc. since November 2, 2023. He holds a B.A. in Political Science and Economics as well as an M.B.A. from Stanford University, which gives him a strong academic foundation in analyzing markets and managing businesses. Before joining Silk Road Medical, he led Apollo Endosurgery, a medical device company, until its acquisition by Boston Scientific Corporation. Over his career, he has also served in executive roles at several other medical device companies, including ROX Medical and Intersect ENT, focusing on commercial development and leadership. Chas brings deep industry knowledge to Silk Road Medical, where he's now tasked with driving innovation in medical technology.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Silk Road Medical CEOs

S

Charles (Chas) McKhann

CEO of Silk Road Medical

Education

B.A. in Political Sciences and Economics and M.B.A. from Stanford University

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1969 - 56 years ago

CEO of Silk Road Medical for

1 year 5 months (Nov 2023 - Present)

Previous Experience

CEO of Apollo Endosurgery, Inc. and various roles in medical device companies

Rivals

Competitors/colleagues of Charles (Chas) McKhann

Holdings

See how much did Charles (Chas) McKhann make over time.

Since taking the helm of Silk Road Medical, Chas McKhann has shown a notable engagement in the company's stock. After his appointment, his holdings fluctuated significantly, starting from around $5.01M in November 2023, as the company's stock positioned itself in...

Since taking the helm of Silk Road Medical, Chas McKhann has shown a notable engagement in the company's stock. After his appointment, his holdings fluctuated significantly, starting from around $5.01M in November 2023, as the company's stock positioned itself in the market. By June 2024, this figure grew to approximately $17.19M, reflecting substantial confidence in the company’s performance and future prospects. As these numbers reveal, Chas is not only leading the company but is also financially tied to its success, indicating a strong level of commitment to Silk Road Medical's growth through his personal investments.

Insider Trading

See recent insider trades of Charles (Chas) McKhann.

SILK

1,299,042 shares

SILK

Sep 17, 2024

Received

SILK

110,313 shares

SILK

Mar 1, 2024

Received

SILK

612,083 shares

SILK

Nov 2, 2023

Received

Compensation History

See how much did Charles (Chas) McKhann make over time.

In 2023, Chas McKhann was compensated with a total package worth around $13.9 million, including a base salary of $650,000 and performance bonuses aligned with company success. His stock awards were notably substantial, including 612,083 restricted stock units (RSUs) that were part of his new hire package, emphasizing a strong link to the company's performance over the next few years. This method ensures that his goals are aligned with stockholder interests, promoting growth and efficiency at Silk Road Medical. He also received a $100,000 sign-on bonus as part of his transition into the CEO role. The compensation structures focus on both attracting high-caliber talent and ensuring long-term commitment to the company's trajectory.

Year

2023

Total Compensation

$8.26M

Salary

$650.00K

Board Justification

The compensation philosophy aligns with company performance, emphasizing pay-for-performance and competitive compensation packages to attract and retain top talent.

Bonus

$93.28K

Board Justification

The target bonus opportunity for our new CEO was set at 100% of his base salary, prorated for 2023, based on performance metrics including revenue growth, operating expense management, and gross margin.

Other

$1.63K

Board Justification

Includes 401(k) match and other benefits.

Restricted Stock

$7.51M(612.08K RSU)

Board Justification

The stock of the CEO that vested in 2023 includes 612,083 RSUs granted as part of his new hire compensation package, which vest annually over four years, subject to continued service.

Performance Metrics

The performance metrics for the 2023 bonus plan included revenue growth over 2022, operating expense management, and gross margin.

Other Silk Road Medical CEOs

Here are other CEOs of Silk Road Medical

Erica J. Rogers

Ex-CEO of Silk Road Medical

November 2012 - November 2023